Published in Cancer on December 15, 1986
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
IFN-α in the treatment of melanoma. J Immunol (2012) 1.12
Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci (2009) 0.92
Neoadjuvant treatment of melanoma: case reports and review. Exp Hematol Oncol (2013) 0.76
Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review. Core Evid (2010) 0.75
Cancer-related fatigue: guidelines for evaluation and management. Oncologist (1999) 9.09
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A (2000) 5.20
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med (1981) 4.90
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med (1990) 3.69
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol (1997) 3.27
Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst (1999) 2.82
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 2.63
Extrapulmonary small cell carcinoma. Cancer (1997) 2.61
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28
13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med (1986) 1.90
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med (1978) 1.74
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70
Locally recurrent non-small-cell lung cancer after complete surgical resection. Mayo Clin Proc (1992) 1.57
Malignant lymphoma of the spleen. A review of 49 cases in which the diagnosis was made at splenectomy. Cancer (1966) 1.54
Phase II evaluation of menogaril in patients with advanced hypernephroma. Invest New Drugs (1991) 1.53
A comparative evaluation of marketed analgesic drugs. N Engl J Med (1972) 1.50
Pulmonary resection for metastatic nonosteogenic sarcoma. Cancer (1979) 1.34
Six families prone to ovarian cancer. Cancer (1975) 1.33
Cancer mortality among American Indians, 1950-67. J Natl Cancer Inst (1972) 1.25
Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med (1988) 1.25
Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer. Cancer Chemother Rep (1975) 1.25
Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer (1989) 1.18
Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA (1995) 1.15
Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol (1986) 1.15
Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med (1979) 1.14
Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer (1991) 1.13
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer (1987) 1.12
Relief of pain by oral medications. A controlled evaluation of analgesic combinations. JAMA (1974) 1.12
Management of nausea and vomiting in the cancer patient. JAMA (1981) 1.11
Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer (1986) 1.08
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol (1995) 1.05
Deaths from brain tumors in eastern Kentucky, 1950-69. J Natl Cancer Inst (1973) 1.05
Non-Hodgkin's lymphoma in childhood: epidemiologic features. J Natl Cancer Inst (1973) 1.04
Safety of pregnancy after discontinuation of isotretinoin. Arch Dermatol (1989) 1.03
A phase I clinical trial of recombinant human tumor necrosis factor. Cancer (1988) 1.02
Metastasis and death in patients with thin melanomas (less than 0.76 mm). Ann Surg (1983) 1.01
Primary leptomeningeal presentation of T-cell lymphoma. Report of a patient and review of the literature. Cancer (1983) 0.99
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol (1987) 0.98
Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep (1983) 0.97
Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol (1986) 0.97
Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report. Cancer (1978) 0.96
Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat Rep (1980) 0.96
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. Cancer (1982) 0.96
Mortality from stomach cancer in coal mining regions. Arch Environ Health (1974) 0.96
Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep (1975) 0.95
Cerebral toxicity in patients treated for small cell carcinoma of the lung. Mayo Clin Proc (1999) 0.95
The urinary excretion of nucleosides of ribonucleic acid by patients with advanced cancer. Cancer (1975) 0.94
Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas. J Clin Oncol (1984) 0.93
Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA (1979) 0.93
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol (1999) 0.91
Estrogen receptors in patients with malignant melanoma. Cancer (1980) 0.91
Primary mediastinal choriocarcinoma. Mayo Clin Proc (1968) 0.91
A design for phase II testing of anticancer agents within a phase III clinical trial. Control Clin Trials (1988) 0.91
Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep (1986) 0.90
Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945-1980. Gynecol Oncol (1989) 0.89
Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancer. Cancer (1983) 0.89
A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol (1982) 0.89
The case of the phantom bladder. J Urol (1997) 0.88
Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma. Cancer Treat Rep (1982) 0.88
Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer (1978) 0.87
Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma. Clin Pharmacol Ther (1976) 0.87
Life-threatening bleomycin pulmonary toxicity with ultimate reversibility. Chest (1990) 0.87
Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol (1987) 0.87
Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep (1977) 0.87
Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer (1996) 0.86
Anti-interferon antibodies: a perspective. Semin Hematol (1988) 0.86
A quantitative approach to determining disease response during therapy using multiple biologic markers: application to carcinoma of the breast. Cancer (1978) 0.86
Beta amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood brain barrier endothelial cell model system. Amyloid (2000) 0.86
A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol (1984) 0.86
Phase I and pharmacokinetic studies of DON. Cancer Treat Rep (1982) 0.86
Survival of patients with extensive small-cell lung cancer who have only brain metastases at initial diagnosis. Am J Clin Oncol (1997) 0.85
Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol (1985) 0.85